Europlasma, a specialist in treatment and hazardous waste, material recovery and decarbonization, issued 500,000 new shares for the benefit of the Global Corporate Finance Opportunities 11 (“GCFO11”) fund, following the exercise by GCFO11 share subscription warrants (the “BSA”) attached to the bonds convertible into new shares issued under the contract for the issuance (the “Contract”) of 10,000 warrants (the “Issue Warrants” ) of OCABSA concluded on April 16, 2021. The Company recalls that it terminated the Contract on October 5 (see press release of October 5, 2022), as such the BSAs issued to GCFO11 under this Contract are the last outstanding securities relating to this Contract.
Pursuant to the decisions of the Chairman and Chief Executive Officer of February 17, 2023, the Company’s share capital was thus increased by an amount of 500,000 euros by issuing 500,000 ordinary shares at a unit price of 1 euro. Through the exercise of 5,000,000,000 BSA, GCFO11 subscribed to these shares and fully paid them up by compensation in proportion to a portion of the certain, liquid and payable debt held on the Company following the sale for its benefit of the loan receivable of €1,419,804 held by the Environmental Performance Financing1 fund. The remaining debt held to date by the latter is thus reduced to €1.3 million (excluding interest).
Through this operation, the Group is continuing its